| Outcome Measures: |
Primary: Change from Baseline in HbA1C at Week 12, Baseline and Week 12|Number of Participants Who Experienced One or More Adverse Events (AE) up to Week 14, Up to Week 14|Number of Participants Who Experienced One or More AE up to Week 54, Up to Week 54|Number of Participants Who Experienced One or More AE up to Week 108, Up to Week 108|Number of Participants Who Experienced One or More AE up to Week 160, Up to Week 160|Number of participants Who Discontinued Study Treatment Due to An AE up to Week 12, Up to Week 12|Number of participants Who Discontinued Study Treatment Due to An AE up to Week 52, Up to Week 52|Number of participants Who Discontinued Study Treatment Due to An AE up to Week 106, Up to Week 106|Number of participants Who Discontinued Study Treatment Due to An AE up to Week 158, Up to Week 158 | Secondary: Change from Baseline in HbA1C at Week 52, Baseline and Week 52|Change from Baseline in HbA1C at Week 106, Baseline and Week 106|Change from Baseline in HbA1C at Week 158, Baseline and Week 158|Change from Baseline in Fasting Plasma Glucose (FPG) at Week 12, Baseline and Week 12|Change from Baseline in FPG at Week 52, Baseline and Week 52|Change from Baseline in FPG at Week 106, Baseline and Week 106|Change from Baseline in FPG at Week 158, Baseline and Week 158|Change from Baseline in Body Weight at Week 12, Baseline and Week 12|Change from Baseline in Body Weight at Week 52, Baseline and Week 52|Change from Baseline in Body Weight at Week 106, Baseline and Week 106|Change from Baseline in Body Weight at Week 158, Baseline and Week 158|Change From Baseline in Serum Fructosamine at Week 12, Baseline and Week 12|Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 12, Baseline and Week 12|Change From Baseline in Daily Seven-Point Fingerstick Glucose Average at Week 52, Baseline and Week 52
|
